The European Commission has authorized Pfizer and BioNTech's updated COVID-19 vaccine for the 2026-2027 season, targeting the XFG variant of the virus. This vaccine is approved for individuals aged 6 months and older and is based on strong clinical and real-world data showing effective immune responses against current and emerging variants. Manufacturing has already begun to meet anticipated demand for the upcoming respiratory disease season. The approval covers all EU member states plus Iceland, Liechtenstein, and Norway, ensuring broad access across Europe.
DelveInsight's 2026 report highlights more than 100 BCMA-targeted therapies in various clinical stages, focusing on multiple myeloma and other diseases. Leading pharma companies like Pfizer, Regeneron, and AstraZeneca are advancing treatments includi...
Pfizer has teamed up with Blackstone to secure up to $1.5 billion in funding for berobenatide, a potential first-in-class monthly GLP-1 agonist aimed at treating obesity. This move is critical as Pfizer faces stagnant revenues, heavy debt, and upcomi...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
